Skip to content

Psilocybin: all studies

Page 243 of 440: studies 2,421 to 2,430 of 4,400, newest first. Back to the psilocybin overview

Research

Towards psychedelic apprenticeship: Developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations.

Transcultural Psychiatry October 1, 2022 Christopher Timmermann, Rosalind Watts, David Dupuis 112 citations

A striking feature of psychedelics is their ability to increase attribution of truth and meaningfulness to specific contents and ideas experienced, which may persist long after psychedelic effects have subsided. We propose that processes underlying conferral of meaning and truth in psychedelic experiences may act as a double-edged sword: while these may drive important therapeutic benefits,...

If the Doors of Perception Were Cleansed, Would Chronic Pain be Relieved? Evaluating the Benefits and Risks of Psychedelics.

Journal of Pain October 1, 2022 Robert H. Dworkin, Brian T Anderson, Nick Andrews et al. 22 citations

Psychedelic substances have played important roles in diverse cultures, and ingesting various plant preparations to evoke altered states of consciousness has been described throughout recorded history. Accounts of the subjective effects of psychedelics typically focus on spiritual and mystical-type experiences, including feelings of unity, sacredness, and transcendence. Over the past 2 decades,...

Why Otolaryngologists Should Be Interested in Psychedelic Medicine.

Otolaryngologic clinics of North America October 1, 2022 Benjamin F Asher

As psychedelic medicine is becoming mainstream, physicians need to know something about these medications, their indications, contraindications, and potential for research. This article is a brief overview of the subject with some ideas of how psychedelic medicines can impact the practice of Otolaryngology-Head and Neck Surgery.

The Emerging Field of Psychedelic Psychotherapy.

Current Psychiatry Reports October 1, 2022 Gregory S. Barber, Scott T Aaronson 56 citations

Few treatments are available for patients with mood disorders or post-traumatic stress disorder (PTSD) who have already failed multiple interventions. After several decades when research into psychedelics was effectively halted by federal legislation, the past several years have shown the re-emergence of thoughtful investigations studying the utility of compounds such as...

Psychedelic medicine at a crossroads: Advancing an integrative approach to research and practice.

Transcultural Psychiatry October 1, 2022 Gabriella Gobbi, Antonio Inserra, Kyle T. Greenway et al. 9 citations

Psychedelics have been already used by human societies for more than 3000 years, mostly in religious and healing context. The renewed interest in the potential application of psychedelic compounds as novel therapeutics has led to promising preliminary evidence of clinical benefit in some psychiatric disorders. Despite these promising results, the potential for large-scale clinical application...

Microdosing with classical psychedelics: Research trajectories and practical considerations

Transcultural Psychiatry October 1, 2022 Alice Wong, Amir Raz 10 citations

Microdosing—the intermittent ingestion of minute, sub-hallucinogenic amounts of psychedelic substances, repeatedly and over time—has become a widespread, albeit largely understudied, phenomenon. Regulations around using psychedelics at any dose—micro, mini, macro, or mega—pose all sorts of difficulties for those who wish to systematically study the effects of Schedule I drugs, especially in the...

Psychedelics and mindfulness: A systematic review and meta-analysis

Journal of Psychedelic Studies September 16, 2022 Chelsea Radakovic, Ratko Radaković, Guy Peryer et al. 23 citations

Abstract Background and aims The benefits of classic serotonergic psychedelics (e.g. psilocybin, LSD, DMT, ayahuasca) are becoming more widely known with the resurgence in research in the past decade. Furthermore, the benefits of mindfulness are well documented. However, no systematic reviews have examined linkage of mindfulness and psychedelics use. The aim of this systematic review is to...

Psychedelic drugs for psychiatric disorders.

Journal of the Neurological Sciences September 15, 2022 Sabrina Correa Da Costa, Tyler Oesterle, Teresa A Rummans et al. 21 citations

Existing pharmacological treatments for psychiatric disorders have demonstrated limited efficacy, delayed onset of action, and significant burden of side effects. Recent findings from human studies with psychedelics have shown promise, demonstrating rapid and sustained clinical benefits of these compounds for a variety of psychiatric disorders. Classical psychedelics have a rich history and...

Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample

International Journal of Environmental Research and Public Health September 9, 2022 Christin Mellner, Micael Dahlen, Otto Simonsson 18 citations

Objectives: Absenteeism from work due to illness, and related costs, has increased steadily during the past decades. In recent years, there has been a reemergence of research on the therapeutic effects of classic psychedelics showing associations with both physical and mental health. However, the association between classic psychedelics and sick leave remains unknown. The aim of this study is...

DOI: 10.3390/ijerph191811353 (opens in new tab) Psilocybin Health economics Public health Sickness absence +7

To treat or not to treat? High-potency benzodiazepine use in a case of comorbid hallucinogen persisting perception disorder and alcohol use disorder.

Experimental and Clinical Psychopharmacology September 1, 2022 Julie A E Christensen, David C. Fipps, J Michael Bostwick 4 citations

Hallucinogen persisting perception disorder (HPPD) is characterized by visual disturbances that resemble psychedelic intoxication and linger after use has ceased. The most common substances precipitating HPPD, lysergic acid diethylamide (LSD) and psilocybin, are posited to do so via damage to serotonergic neurons involved in vision. Mr. N is a 37-year-old with a history of alcohol, cannabis,...